HIGH

Lupin Pharmaceuticals Recalls Ganirelix Acetate Injection for Impurity Risk

Lupin Pharmaceuticals recalled 32,736 vials of Ganirelix Acetate Injection on November 13, 2025. The recall follows the discovery of impurities in the drug. Consumers and healthcare providers should stop using the product immediately to avoid health risks.

Quick Facts at a Glance

Recall Date
November 13, 2025
Hazard Level
HIGH
Brands
GANIRELIX ACETATE, Lupin Pharmaceuticals, Inc.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
4 states
At-Risk Groups
GENERAL

Hazard Information

Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Lupin Pharmaceuticals Inc. or your healthcare provider for guidance. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Ganirelix Acetate Injection is a medication used in assisted reproductive technology to prevent premature ovulation. Patients typically receive this injection under the guidance of a healthcare provider during fertility treatments.

Why This Is Dangerous

The recall stems from the presence of an impurity that failed to meet safety specifications. This impurity could lead to adverse health effects, making it unsafe for patient use.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

Consumers are advised to stop using the product immediately, as this could pose serious health risks. The inconvenience and potential health implications highlight the importance of monitoring medication quality.

Practical Guidance

How to identify if yours is affected

  1. Check the lot number on your Ganirelix Acetate Injection.
  2. Verify if it matches Lot #: WB00006.
  3. Look for the expiration date of December 31, 2026.

Where to find product info

Lot number and expiration date can be found on the packaging of the prefilled syringe.

What timeline to expect

Expect a refund or replacement to process within 4-6 weeks after contacting the manufacturer.

If the manufacturer is unresponsive

  • Document all correspondence with the manufacturer.
  • Follow up via phone or email after one week if no response is received.

How to prevent similar issues

  • Always check for recall notices before using medications.
  • Consult with healthcare providers regularly about medication safety.
  • Look for FDA approval and recall history when purchasing medications.

Documentation advice

Keep receipts, product lot numbers, and any communication with the manufacturer for your records.

Product Details

Ganirelix Acetate Injection comes in a 250 mcg/0.5 mL single-dose sterile prefilled syringe with a 27 gauge by 1/2' needle. The affected lot number is WB00006, with an expiration date of December 31, 2026. The product was distributed in Florida, Massachusetts, Michigan, and Ohio.

Key Facts

  • 32,736 vials recalled
  • Lot #: WB00006
  • Exp. date: 12/31/2026
  • Distributed in FL, MA, MI, OH
  • Stop use immediately

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product Details

Model Numbers
Lot #: WB00006
Exp 12/31/2026
UPC Codes
70748-274
70748-274-01
Affected States
FL, MA, MI, OH
Report Date
December 17, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more